Acute myocardial infarction induced by nilotinib
10.3760/cma.j.cn114015-20190722-00599
- VernacularTitle:尼洛替尼诱发急性心肌梗死
- Author:
Ruipeng GUO
1
;
Guoxiang ZHANG
1
;
Xuliang SHEN
1
Author Information
1. 山西省长治医学院附属和平医院血液科 046000
- Publication Type:Journal Article
- Keywords:
Antineoplastic agents;
Leukemia, myeloid, chronic-phase;
Myocardial infarction;
Nilotinib
- From:
Adverse Drug Reactions Journal
2020;22(9):535-536
- CountryChina
- Language:Chinese
-
Abstract:
A 62-year-old male patient with chronic myelogenous leukemia (chronic phase) received nilotinib 400 mg twice daily. The patient developed mild fatigue, precordial discomfort, and chest tightness 5 hours after the first medication, which were relieved after rest. One hour after the second medication on the same day, the symptoms of precordial discomfort and chest tightness recurred, and they were relieved after rest again. One hour after taking the medicine again the next day, the above symptoms recurred and were aggravated, which could not be relieved after rest. Laboratory tests showed that serum troponin I was 2.67 μg/L, myoglobin was 195.1 μg/L, and creatine kinase MB was 37.7 μg/L. Electrocardiogram (ECG) showed that ST segment depression was >0.1 mV in leads I, II, III, aVL, aVF, and V 1-V 6, T-wave inversion, and QT/QTc was 350/402 ms. The patient was diagnosed as having acute non-ST segment elevation myocardial infarction, which was considered to be related to nilotinib. After 3 weeks of drug withdrawal and vasodilator and anticoagulant therapy, the laboratory tests showed that serum troponin I was not detected, myoglobin was 21.7 μg/L, and creatine kinase MB was 0.8 μg/L. ECG examination showed ST segment depression and T-wave inversion disappeared in leads I, II, III, aVL, aVF and V 1-V 6, and QT/QTc was 370/376ms.
